Throughout 2009, NFI has assisted MediSend by transporting biomedical provisions and equipment from donor hospitals in the U.S. to the non-profit’s distribution center in Dallas, Texas, where the items are readied for international shipment to hospitals and clinics in the world’s poorest countries such as Equatorial Guinea, Angola, Chad and Bangladesh.

Related posts

• Alliance HealthCare Services Receives National Award for Exceeding Patient Expectations (0)
• MEDNAX to present at Jefferies & Company, Inc. Third Annual Healthcare Conference (0)
• Array BioPharma to Present at the Jefferies 3rd Annual Healthcare Conference (0)
• NPS Pharmaceuticals to Present at Jefferies Healthcare Conference (0)
• OSI Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference on Tuesday, June 9, 2009 (0)

Related posts

• Health Evolution Partners Announces Second Investment in Medical Imaging (0)
• Advantage Medical Devices Receives FDA Clearance for VantageCath (0)
• FDA Clears First Medical Product Made From Yulex Natural Rubber (0)
• Novel Antipsychotic Drug for Patients with Schizophrenia (0)

Related posts

• Patients, Caregivers Can Learn to Manage Diabetes at Rite Aid Clinics June 23, 25 (0)
• VIAject Presentations at ADA Meeting Highlight Drug’s Mechanism of Absorption and Microvascular Effects (0)
• International Diabetes Study Establishes GlycoMark as Definitive Test for Blood Sugar Swings in Seemingly Well-Controlled Patients (0)
• Medtronic Highlights New Advances in Development of Closed-Loop System for Diabetes Management (0)
• VeroScience Presents Data on Newly FDA Approved Drug Cycloset at American Diabetes Association Annual Scientific Sessions (0)

Related posts

• Biotech Leaders, Patient Advocates Highlight Cutting-Edge HIV/AIDS Therapies, Need for Next Generation Treatments (0)
• AIDS Patients with Serious Complications Benefit from Early Retroviral Use, Stanford Study Shows (0)
• SiDMAP, LLC Enters Japanese Market for Pharmaceutical Research Services with Two New Contracts for Metabolomics Testing and Biomarker Development (0)
• Novel Antipsychotic Drug for Patients with Schizophrenia (0)

Commending Alliance, David Medvedeff, PharmD, MBA, CEO of Avatar, said, “The hallmark of exceptional service to patients is to consistently meet or exceed their expectations — not always an easy task. Alliance has demonstrated that it exceeds its patients’ expectations in a tangible and measurable manner. As a winner of Avatar’s Exceeding Patient Expectations Award, I congratulate Alliance for its continued and impressive efforts to put patients first.”

Related posts

• MEDNAX to present at Jefferies & Company, Inc. Third Annual Healthcare Conference (0)
• Array BioPharma to Present at the Jefferies 3rd Annual Healthcare Conference (0)
• NPS Pharmaceuticals to Present at Jefferies Healthcare Conference (0)
• OSI Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference on Tuesday, June 9, 2009 (0)
• XenoPort to Present at the Goldman Sachs 30th Annual Global Healthcare Conference (0)

“This was our 129th implant of the Total Artificial Heart,” said implanting surgeon Dr. Latif Arusoglu. “The Total Artificial Heart is the only device that pumps up to 9.5 L/min through both ventricles, helping us to rescue the sickest of the sick.”

Dr. Arusoglu brought the Total Artificial Heart to the Heart & Diabetes Center NRW and performed the hospital’s first implant in 2001. As an instructor for SynCardia’s Certification Program, Dr. Arusoglu proctors top European transplant centers during their first implant. The Heart & Diabetes Center NRW has performed more Artificial Heart implants than any other center in Germany.

“Our Total Artificial Heart patients can wait up to 2 years for a matching donor heart,” explained Prof. Jan Gummert, M.D., Director of the Clinic for Thoracic and Cardiovascular Surgery. “The portable driver allows stable patients to enjoy an active lifestyle at home and in their communities, similar to people with healthy human hearts.”

Related posts

• Direct Flow Medical Announces Fifth Patent Issuance of Their Unique Percutaneous Aortic Valve Technology (0)
• Disc Motion Technologies, the First Company to Commercialize the Posteriorly Total Motion Segment System for the Lumbar Spine, Announces the First Surgical Procedure Using Inlign Multi-Level Hybrid System (0)
• St. Jude Medical Announces European Approval of Its Newest Heart Failure Devices Which Enable More Efficient Implantation and Follow-up (0)
• TCF Bank Kenosha Branch Hosts a Bone Marrow and Blood Drive for Stephanie Ramirez (0)
• First Implant of a New-Generation CRT-D Device (0)

The free events are part of Rite Aid’s year-round focus helping diabetes patients take the best care of themselves. The events include blood pressure screenings, personal pharmacist consultations and glucose meter selection and training. There also will be product coupons and samples of the latest in at-home diabetes care, and visitors can enter a raffle at each location for a $50 Rite Aid gift card.

“The key to effective diabetes management is to understand the condition’s symptoms and treatments. On Diabetes Solutions Day, patients can consult with trained Rite Aid pharmacists on their diabetes symptoms and treatment regimen as well as sample the latest techniques in at-home monitoring,” said Robert Thompson, Rite Aid senior vice president of pharmacy.

Related posts

• Home Diagnostics Launches TRUEmanager Diabetes Management Software (0)
• VIAject Presentations at ADA Meeting Highlight Drug’s Mechanism of Absorption and Microvascular Effects (0)
• International Diabetes Study Establishes GlycoMark as Definitive Test for Blood Sugar Swings in Seemingly Well-Controlled Patients (0)
• Medtronic Highlights New Advances in Development of Closed-Loop System for Diabetes Management (0)
• VeroScience Presents Data on Newly FDA Approved Drug Cycloset at American Diabetes Association Annual Scientific Sessions (0)

Michael Longaker, MD, deputy director of Stanford’s Stem Cell Biology and Regenerative Medicine Institute, is principal investigator of the Stanford training grant, which will fund graduate students, postdoctoral scholars and clinical fellows working in stem cell research labs.

“Our first round of training grants have funded an extremely productive group of young researchers,” said CIRM president Alan Trounson in a prepared statement. “It’s important that we continue supporting these future stem cell scientists who are already making significant contributions to the field.”

In total, Stanford has received $107 million in grants from the state’s stem cell agency.

Related posts

• Osiris Therapeutics to Present at Piper Jaffray Conference (0)
• NERI and ProMedica CRC Form Strategic Alliance to Support Phase I-IV Clinical Research Studies (0)
• Northfield Laboratories Announces Decision to Wind Down Business (0)
• BioTime CEO Dr. Michael West to Present at World Stem Cells & Regenerative Medicine Congress 2009 and Discuss New Cell Lines with Cartilage-Forming Potential (0)
• Stanford Researchers Receive $5.8 Million Grant from State Stem Cell Agency (0)

The real-time integrated operation of the new AutoPulse Plus and the E Series coordinates the ability to provide consistent, uninterrupted chest compressions with timed shock delivery. Integrating these two therapeutic interventions into a seamless rescue effort has long been viewed as critical to advancing resuscitation care. Stopping chest compressions during defibrillation results in a rapid fall in coronary perfusion pressure. Both the AutoPulse Plus and the E Series have the CE Mark; however, the new AutoPulse Plus does not yet have 510(k) FDA clearance in the U.S.

Related posts

• St. Jude Medical Announces European Approval of Its Newest Heart Failure Devices Which Enable More Efficient Implantation and Follow-up (0)
• First Implant of a New-Generation CRT-D Device (0)

“This new guidance from NICE gives clinicians access to a much needed option for patients with multiple myeloma who are not responding to other treatments,” said Steve Schey, Consultant Haematologist and lead for myeloma at Kings College Hospital and Chair of the UK Myeloma Forum. “As the disease progresses, patients and clinicians need ready access to treatments like REVLIMID that can prolong a patient’s life and help transform an incurable blood cancer into a chronic, manageable condition.”

Following the appraisal process, NICE concluded in May of this year that REVLIMID is an innovative, life-extending therapy, and a cost-effective use of National Health Service (NHS) resources. In clinical trials, survival was significantly extended for patients taking REVLIMID with dexamethasone and time to disease progression doubled, compared to treatment with dexamethasone alone. In addition, the majority of patients on REVLIMID/dexamethasone treatment experienced a reduction in signs and symptoms of myeloma.

“Celgene is pleased that REVLIMID will now be available for multiple myeloma patients in England and Wales enabling them to live longer with more productive lives,” said Tuomo Pätsi, Celgene’s Regional Vice-President, Northern Europe. “NICE’s decision is a welcome recognition of the value of oral medicines like, REVLIMID, which allow patients to take their treatments at home freeing up healthcare resources.”

The recommendation from NICE extends from new appraisal criteria, which recognise REVLIMID as an end-of-life medicine, in conjunction with a proposal by REVLIMID manufacturer, Celgene Limited, to meet costs of treatment for patients who must remain on REVLIMID past 26 cycles of treatment, which typically last over a period of two years.

Eric Low, Chief Executive of Myeloma UK commented, “We at Myeloma UK applaud the efforts of the myeloma community, the manufacturer, NICE and the Department of Health for enabling access to this important treatment. We eagerly encourage Primary Care Trusts to implement this long-anticipated guidance to ensure immediate access for patients in need.”

NICE’s evaluation considered peer-reviewed clinical studies that demonstrated REVLIMID offers significant improvement in overall survival, deep and durable responses that improve over time and a manageable side-effect profile that is acceptable for long-term use. Data has shown that in 2 out of 3 patients taking REVLIMID plus dexamethasone the signs and symptoms of their cancer were substantially reduced, resulting in many patients living virtually symptom-free, compared with 1 out of 4 patients taking dexamethasone alone. REVLIMID gives patients the opportunity to live longer with their cancer controlled, and represents a major step forward towards turning this devastating blood cancer into a chronic disease.

Related posts

• MRI Data Showing TYSABRI Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology (0)
• Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors (0)